Analyst Price Targets — IMDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 1:48 pm | — | Lake Street | $12.00 | $5.33 | TheFly | Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street |
| November 11, 2025 9:51 am | Mike Matson | Needham | $9.00 | $6.80 | StreetInsider | Insight Molecular Diagnostics Inc. (IMDX) PT Raised to $9 at Needham |
| May 21, 2025 12:42 pm | Thomas Flaten | UBS | $8.00 | $3.07 | TheFly | OncoCyte price target raised to $8 from $5 at Lake Street |
| April 24, 2024 10:38 am | Mike Matson | Needham | $4.25 | $2.38 | StreetInsider | OncoCyte Corp (OCX) PT Raised to $4.25 at Needham |
| December 1, 2022 9:13 am | — | Lake Street | $10.00 | $9.44 | Benzinga | Lake Street Downgrades OncoCyte to Hold, Lowers Price Target to $0.5 |
| November 18, 2022 5:05 am | — | Piper Sandler | $10.00 | $8.52 | Benzinga | Piper Sandler Downgrades OncoCyte to Neutral, Lowers Price Target to $0.5 |
| August 17, 2022 9:42 pm | David Westenberg | Piper Sandler | $30.00 | $17.48 | TheFly | OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler |
| August 11, 2022 10:43 am | — | Lake Street | $60.00 | $19.27 | Benzinga | Lake Street Maintains Buy on OncoCyte, Lowers Price Target to $3 |
| August 11, 2022 5:31 am | — | Needham | $42.00 | $19.02 | Benzinga | Needham Maintains Buy on OncoCyte, Lowers Price Target to $2.1 |
| May 15, 2022 9:15 pm | David Westenberg | Piper Sandler | $28.00 | $22.60 | TheFly | OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler |
Latest News for IMDX
NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the publication of a new peer-reviewed study demonstrating the potential superiority of the company's flagship GraftAssureTM assay technology.
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations. Profitability This table compares Anbio Biotechnology and Oncocyte's net
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) are both manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership. Analyst Recommendations This is a breakdown of current ratings
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) are both manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, institutional ownership, valuation, earnings and analyst recommendations. Valuation and Earnings This table compares Anbio Biotechnology and
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) are both manufacturing companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Analyst Ratings This is a summary of current ratings
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMDX.
U.S. House Trading
No House trades found for IMDX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.